Who was studied?
Planned enrollment: 62 patients with HER2-expressing advanced refractory solid tumors.
What does the publication report?
The primary planned endpoint is objective response rate, with survival, safety and quality-of-life assessments.
Safety findings
No completed trial toxicity rates are provided in this protocol.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol) · DOI: 10.1177/15330338261432537 · PMID: 41823246
Related publications from the same research program
- Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities
- A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors.
- An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0).
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.